Altrova Health Provides Corporate Update: New OTCQB Symbol, O-Spray Progress, NIRLAB Device Sale, and Detection Strip Expansion
CSE: ROVA | OTCQB: ATVHF | FSE: WF8
Overview
Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) issued a corporate update on July 22, 2026, covering developments across its trading symbol, product lines, advisory board, and a correction to a prior press release.
The company reported that its common shares commenced trading on the OTCQB under the new ticker symbol "ATVHF," effective as of market open on July 17, 2026, replacing the prior symbol "SSPLF." According to the company, the change does not affect the Company's share structure, CUSIP, or its listing on the Canadian Securities Exchange, where shares continue to trade under "ROVA."
Key Highlights
- The company's OTCQB ticker changed from "SSPLF" to "ATVHF," effective July 17, 2026, to align the company's US trading identity with the Altrova Health name and brand.
- Altrova Health announced the sale of an additional NIRLAB SA NIRLIGHT drug analysis device to a First Nation community, expanding the device's presence within Indigenous community safety initiatives.
- The company is advancing a new commercial strategy for its rapid detection strip portfolio through its wholly owned subsidiary, Drug Lab 118 Ltd. ("Drug Lab US"), described as a rebrand and commercial relaunch under the Altrova Health umbrella.
- Drug Lab US's core product lines, Drink Detective, Drug Detective, and Fentanyl Detective, are being targeted for distribution scaling across the United States and Canada, with a focus on educational institutions, hospitality operators, and municipal and public safety stakeholders.
- The company is onboarding two new advisors: Castlewood Capital Corporation and Blaise Yerly.
- The company confirmed that statements in its July 2, 2026 press release regarding Raf Souccar continuing in an advisory capacity following his resignation as Chairman were included in error; Mr. Souccar is not serving, and has not agreed to serve, in any capacity with the company.
O-Spray Commercial Update
According to the company, Altrova Health has been engaged in ongoing discussions with prospective distribution and licensing partners to expand O-Spray's reach across retail and healthcare practitioner channels. Management believes these partnership discussions, if concluded, would meaningfully accelerate O-Spray's market penetration, and the company looks forward to providing further updates as agreements are finalized.
Drug Lab US Rapid Detection Portfolio
Drug Lab US's three core product lines address two public health priorities as described by the company. Drink Detective is engineered to identify illicit substances and sedatives concealed in drinks. Drug Detective offers surface-testing to detect trace drug residue on personal property and packaging. Fentanyl Detective delivers rapid, accurate detection of fentanyl and its analogs in high-risk environments. The company states it is focused on scaling distribution of this portfolio across the United States and Canada, targeting educational institutions, hospitality operators, and municipal and public safety stakeholders.
Advisory Board Update
The company is onboarding Jason Libenson, President and Chief Operating Officer of Castlewood Capital Corporation, who brings over ten years of experience in financial services, having held senior roles with several asset managers and raised capital across mutual funds, hedge funds, and flow-through fund structures. He has also served on the boards of various public companies. Mr. Libenson holds a Bachelor of Commerce from Concordia University and resides in Toronto.
Blaise Yerly brings over 30 years of experience in Canadian public markets as both an investor and director. He previously served as a director and Chairman of Aquiline Resources, acquired by Pan American Silver in 2009 for over $620 million in stock, and as a director of Treasury Metals (now NeXGold Mining) from 2008 to 2018 and Cypherpunk Holdings (now Sol Strategies Inc.) from 2017 to 2021. Mr. Yerly has served as Executive Chairman of Wacyba Ltd, a Swiss-based family holding company, since 2008, and has previously built and sold a heavy equipment distribution business in sub-Saharan Africa along with a related asset-based finance company.
"Jason and Blaise bring exactly the kind of capital markets and public company experience we want around the table as Altrova Health scales," said Geoff Benic, Chief Executive Officer of Altrova Health. "Jason's track record raising capital across a range of investment vehicles, paired with Blaise's three decades building and directing public companies, gives us valuable perspective as we advance our commercial strategy across O-Spray, NIRLAB, and our rapid detection portfolio."
What to Watch Next
- The company stated it looks forward to providing further updates as O-Spray distribution and licensing agreements are finalized.
- Drug Lab US commercial strategy scaling across the United States and Canada is ongoing, according to the company.
- Continued expansion of NIRLAB device presence across Canada is described as ongoing.
About Altrova Health Inc.
Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) is a Canadian public company building a growing portfolio of health solutions across detection, protection, treatment, and wellness. The Company's current product portfolio includes exclusive Canadian distribution rights for the NIRLAB SA ("NIRLAB") NIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking detection product line, and the O-Spray product line, alongside the rapid detection strip portfolio of its subsidiary Drug Lab 118 Ltd.
Disclaimer and Forward-Looking Statements
The information contained herein is provided by ArcStone Financial Pulse Inc. ("ArcStone Financial Pulse"), a subsidiary of ArcStone Securities and Investments Corp. ("ArcStone"), for informational purposes only. It is not, and under no circumstances should it be construed as, an offer to sell or a solicitation of an offer to buy any securities or other financial instruments in any jurisdiction. This content is not a research report within the meaning of FINRA Rules 2241 or 2242 and does not constitute a research report under any applicable securities laws.
Certain statements contained herein may constitute "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements are based on current expectations, estimates, and assumptions that involve known and unknown risks and uncertainties which may cause actual results or developments to differ materially from those expressed or implied. These statements often include words such as "anticipate," "believe," "expect," "intend," "may," "plan," "project," "should," "target," or similar expressions. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. Except as required by law, ArcStone undertakes no obligation to update or revise any forward-looking information.
This content is not intended as investment advice or a recommendation to buy or sell any security and does not take into account the investment objectives, financial situation, or needs of any individual. Investors should consult their own professional advisors before making any investment decisions.
ArcStone Securities and Investments Corp. is not a registered broker-dealer and does not provide investment advice or recommendations. All registrable activities in the United States are conducted through ArcStone Securities, LLC (CRD# 306029) and/or Kingswood Capital Partners, LLC (CRD# 288898), both FINRA-registered broker-dealers, members SIPC. ArcStone Canada Inc. is not registered as a dealer in any Canadian jurisdiction; registrable dealing activities in Canada are conducted through appropriately registered affiliates.
ArcStone Kingswood is a DBA Office of Supervisory Jurisdiction (OSJ) of Kingswood Capital Partners, LLC (Member FINRA/SIPC) under which registered representatives of ArcStone Securities, LLC (Member FINRA/SIPC) and registered representatives of Kingswood Capital Partners, LLC conduct joint capital markets and investment banking activities. ArcStone Securities, LLC and Kingswood Capital Partners, LLC are parties to a written agreement governing the sharing of fees on transactions in which registered representatives of both firms participate. All securities transactions and investment banking services described in this article are conducted exclusively through ArcStone Securities, LLC and/or Kingswood Capital Partners, LLC; "ArcStone Kingswood" itself is not a registered broker-dealer or separate legal entity.
ArcStone Financial Pulse Inc. is owned by the same parent entity (ArcStone Securities and Investments Corp.) that owns ArcStone Securities, LLC. This common ownership, together with the joint operating relationship between ArcStone Securities, LLC and Kingswood Capital Partners, LLC under the ArcStone Kingswood DBA OSJ banner, represents a structural conflict of interest. The issuer featured in this article (the "Company") may be a current or former client of ArcStone or any of its subsidiaries and affiliates. Where ArcStone or its subsidiaries and affiliates have received or have been promised consideration for services provided to the Company, such consideration may include cash, stock, stock options, warrants, and/or Restricted Stock Units (RSUs) for the provision of corporate advisory, investor relations, digital media, or capital markets consulting services. This relationship represents a potential conflict of interest, as ArcStone may be perceived to have an incentive to present the Company in a favorable light. The principals, directors, officers, employees, and related entities of ArcStone and its affiliates may, from time to time, own, buy, or sell securities or derivatives of the Company or its affiliates.
